The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care

Polygenic risk scores (PRSs) hold promise for disease risk assessment and prevention. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRSs in preventive care: defining and determining their clinical utility, implementing t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of human genetics 2023-11, Vol.110 (11), p.1841-1852
Hauptverfasser: Vassy, Jason L., Brunette, Charles A., Lebo, Matthew S., MacIsaac, Katharine, Yi, Thomas, Danowski, Morgan E., Alexander, Nicholas V.J., Cardellino, Mark P., Christensen, Kurt D., Gala, Manish, Green, Robert C., Harris, Elizabeth, Jones, Natalie E., Kerman, Benjamin J., Kraft, Peter, Kulkarni, Preetika, Lewis, Anna C.F., Lubitz, Steven A., Natarajan, Pradeep, Antwi, Ashley A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1852
container_issue 11
container_start_page 1841
container_title American journal of human genetics
container_volume 110
creator Vassy, Jason L.
Brunette, Charles A.
Lebo, Matthew S.
MacIsaac, Katharine
Yi, Thomas
Danowski, Morgan E.
Alexander, Nicholas V.J.
Cardellino, Mark P.
Christensen, Kurt D.
Gala, Manish
Green, Robert C.
Harris, Elizabeth
Jones, Natalie E.
Kerman, Benjamin J.
Kraft, Peter
Kulkarni, Preetika
Lewis, Anna C.F.
Lubitz, Steven A.
Natarajan, Pradeep
Antwi, Ashley A.
description Polygenic risk scores (PRSs) hold promise for disease risk assessment and prevention. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRSs in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities. The study processes used to test patients, report their PRS results to them and their primary care providers (PCPs), and promote the use of those results in clinical decision-making are modeled on common practices in primary care. The following diseases were chosen for their prevalence and familiarity to PCPs: coronary artery disease; type 2 diabetes; atrial fibrillation; and breast, colorectal, and prostate cancers. A randomized clinical trial (RCT) design and primary outcome of time-to-new-diagnosis of a target disease bring methodological rigor to the question of the clinical utility of PRS implementation. The study’s pragmatic RCT design enhances its relevance to how PRS might reasonably be implemented in primary care. Steps the study has taken to promote health equity include the thoughtful handling of genetic ancestry in PRS construction and reporting and enhanced recruitment strategies to address underrepresentation in research participation. To date, enhanced recruitment efforts have been both necessary and successful: participants of underrepresented race and ethnicity groups have been less likely to enroll in the study than expected but ultimately achieved proportional representation through targeted efforts. The GenoVA Study experience to date offers insights for evaluating the clinical utility of equitable PRS implementation in adult primary care. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRS in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities.
doi_str_mv 10.1016/j.ajhg.2023.10.001
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10645559</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002929723003543</els_id><sourcerecordid>2886602555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-3ec63d209155b7dc3a1ad8a2eecf563c66f27e64512900d49e9622c5082eddc23</originalsourceid><addsrcrecordid>eNp9kU9v3CAQxVHVqtmm_QI9VBx78YY_C7arSlUUpUmkSL0kuSIWxl62NmwAR9p--mDtNmovOSFmfvMY3kPoMyVLSqg82y71dtMvGWG8FJaE0DdoQQWvKymJeIsWhBBWtaytT9CHlLYFoA3h79EJr1vGmoYvUL7bAL4CHx7OccqT3X_Dl4-Ty3o9AHbjboARfNbZBY9DhzXeRd2P5W5w1N6G0f0Bi3N0epj7uzDse_DOVNGl3ziZEJ3vsfNlzo067rHRET6id50eEnw6nqfo_ufl3cV1dfvr6ubi_LYyKyFzxcFIbhlpqRDr2hquqbaNZgCmE5IbKTtWg1wJylpC7KqFVjJmBGkYWGsYP0U_Drq7aT2CNeUnUQ_quIoK2qn_O95tVB-eFCVFVYi2KHw9KsTwOEHKanTJwDBoD2FKqphYvGaFLSg7oCaGlCJ0L-9Qoua81FbNeak5r7lW4ihDX_7d8GXkb0AF-H4AoPj05CCqZBx4A9ZFMFnZ4F7TfwbOiKlV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886602555</pqid></control><display><type>article</type><title>The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care</title><source>MEDLINE</source><source>PMC (PubMed Central)</source><source>Elsevier ScienceDirect Journals Complete</source><source>Cell Press Free Archives</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Vassy, Jason L. ; Brunette, Charles A. ; Lebo, Matthew S. ; MacIsaac, Katharine ; Yi, Thomas ; Danowski, Morgan E. ; Alexander, Nicholas V.J. ; Cardellino, Mark P. ; Christensen, Kurt D. ; Gala, Manish ; Green, Robert C. ; Harris, Elizabeth ; Jones, Natalie E. ; Kerman, Benjamin J. ; Kraft, Peter ; Kulkarni, Preetika ; Lewis, Anna C.F. ; Lubitz, Steven A. ; Natarajan, Pradeep ; Antwi, Ashley A.</creator><creatorcontrib>Vassy, Jason L. ; Brunette, Charles A. ; Lebo, Matthew S. ; MacIsaac, Katharine ; Yi, Thomas ; Danowski, Morgan E. ; Alexander, Nicholas V.J. ; Cardellino, Mark P. ; Christensen, Kurt D. ; Gala, Manish ; Green, Robert C. ; Harris, Elizabeth ; Jones, Natalie E. ; Kerman, Benjamin J. ; Kraft, Peter ; Kulkarni, Preetika ; Lewis, Anna C.F. ; Lubitz, Steven A. ; Natarajan, Pradeep ; Antwi, Ashley A.</creatorcontrib><description>Polygenic risk scores (PRSs) hold promise for disease risk assessment and prevention. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRSs in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities. The study processes used to test patients, report their PRS results to them and their primary care providers (PCPs), and promote the use of those results in clinical decision-making are modeled on common practices in primary care. The following diseases were chosen for their prevalence and familiarity to PCPs: coronary artery disease; type 2 diabetes; atrial fibrillation; and breast, colorectal, and prostate cancers. A randomized clinical trial (RCT) design and primary outcome of time-to-new-diagnosis of a target disease bring methodological rigor to the question of the clinical utility of PRS implementation. The study’s pragmatic RCT design enhances its relevance to how PRS might reasonably be implemented in primary care. Steps the study has taken to promote health equity include the thoughtful handling of genetic ancestry in PRS construction and reporting and enhanced recruitment strategies to address underrepresentation in research participation. To date, enhanced recruitment efforts have been both necessary and successful: participants of underrepresented race and ethnicity groups have been less likely to enroll in the study than expected but ultimately achieved proportional representation through targeted efforts. The GenoVA Study experience to date offers insights for evaluating the clinical utility of equitable PRS implementation in adult primary care. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRS in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities.</description><identifier>ISSN: 0002-9297</identifier><identifier>EISSN: 1537-6605</identifier><identifier>DOI: 10.1016/j.ajhg.2023.10.001</identifier><identifier>PMID: 37922883</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Diabetes Mellitus, Type 2 - genetics ; Genetic Predisposition to Disease ; Humans ; Male ; Primary Health Care ; Prostatic Neoplasms - genetics ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors</subject><ispartof>American journal of human genetics, 2023-11, Vol.110 (11), p.1841-1852</ispartof><rights>2023</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-3ec63d209155b7dc3a1ad8a2eecf563c66f27e64512900d49e9622c5082eddc23</citedby><cites>FETCH-LOGICAL-c456t-3ec63d209155b7dc3a1ad8a2eecf563c66f27e64512900d49e9622c5082eddc23</cites><orcidid>0000-0001-6113-5564</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645559/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002929723003543$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,3537,27901,27902,53766,53768,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37922883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vassy, Jason L.</creatorcontrib><creatorcontrib>Brunette, Charles A.</creatorcontrib><creatorcontrib>Lebo, Matthew S.</creatorcontrib><creatorcontrib>MacIsaac, Katharine</creatorcontrib><creatorcontrib>Yi, Thomas</creatorcontrib><creatorcontrib>Danowski, Morgan E.</creatorcontrib><creatorcontrib>Alexander, Nicholas V.J.</creatorcontrib><creatorcontrib>Cardellino, Mark P.</creatorcontrib><creatorcontrib>Christensen, Kurt D.</creatorcontrib><creatorcontrib>Gala, Manish</creatorcontrib><creatorcontrib>Green, Robert C.</creatorcontrib><creatorcontrib>Harris, Elizabeth</creatorcontrib><creatorcontrib>Jones, Natalie E.</creatorcontrib><creatorcontrib>Kerman, Benjamin J.</creatorcontrib><creatorcontrib>Kraft, Peter</creatorcontrib><creatorcontrib>Kulkarni, Preetika</creatorcontrib><creatorcontrib>Lewis, Anna C.F.</creatorcontrib><creatorcontrib>Lubitz, Steven A.</creatorcontrib><creatorcontrib>Natarajan, Pradeep</creatorcontrib><creatorcontrib>Antwi, Ashley A.</creatorcontrib><title>The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care</title><title>American journal of human genetics</title><addtitle>Am J Hum Genet</addtitle><description>Polygenic risk scores (PRSs) hold promise for disease risk assessment and prevention. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRSs in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities. The study processes used to test patients, report their PRS results to them and their primary care providers (PCPs), and promote the use of those results in clinical decision-making are modeled on common practices in primary care. The following diseases were chosen for their prevalence and familiarity to PCPs: coronary artery disease; type 2 diabetes; atrial fibrillation; and breast, colorectal, and prostate cancers. A randomized clinical trial (RCT) design and primary outcome of time-to-new-diagnosis of a target disease bring methodological rigor to the question of the clinical utility of PRS implementation. The study’s pragmatic RCT design enhances its relevance to how PRS might reasonably be implemented in primary care. Steps the study has taken to promote health equity include the thoughtful handling of genetic ancestry in PRS construction and reporting and enhanced recruitment strategies to address underrepresentation in research participation. To date, enhanced recruitment efforts have been both necessary and successful: participants of underrepresented race and ethnicity groups have been less likely to enroll in the study than expected but ultimately achieved proportional representation through targeted efforts. The GenoVA Study experience to date offers insights for evaluating the clinical utility of equitable PRS implementation in adult primary care. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRS in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities.</description><subject>Adult</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>Male</subject><subject>Primary Health Care</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><issn>0002-9297</issn><issn>1537-6605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v3CAQxVHVqtmm_QI9VBx78YY_C7arSlUUpUmkSL0kuSIWxl62NmwAR9p--mDtNmovOSFmfvMY3kPoMyVLSqg82y71dtMvGWG8FJaE0DdoQQWvKymJeIsWhBBWtaytT9CHlLYFoA3h79EJr1vGmoYvUL7bAL4CHx7OccqT3X_Dl4-Ty3o9AHbjboARfNbZBY9DhzXeRd2P5W5w1N6G0f0Bi3N0epj7uzDse_DOVNGl3ziZEJ3vsfNlzo067rHRET6id50eEnw6nqfo_ufl3cV1dfvr6ubi_LYyKyFzxcFIbhlpqRDr2hquqbaNZgCmE5IbKTtWg1wJylpC7KqFVjJmBGkYWGsYP0U_Drq7aT2CNeUnUQ_quIoK2qn_O95tVB-eFCVFVYi2KHw9KsTwOEHKanTJwDBoD2FKqphYvGaFLSg7oCaGlCJ0L-9Qoua81FbNeak5r7lW4ihDX_7d8GXkb0AF-H4AoPj05CCqZBx4A9ZFMFnZ4F7TfwbOiKlV</recordid><startdate>20231102</startdate><enddate>20231102</enddate><creator>Vassy, Jason L.</creator><creator>Brunette, Charles A.</creator><creator>Lebo, Matthew S.</creator><creator>MacIsaac, Katharine</creator><creator>Yi, Thomas</creator><creator>Danowski, Morgan E.</creator><creator>Alexander, Nicholas V.J.</creator><creator>Cardellino, Mark P.</creator><creator>Christensen, Kurt D.</creator><creator>Gala, Manish</creator><creator>Green, Robert C.</creator><creator>Harris, Elizabeth</creator><creator>Jones, Natalie E.</creator><creator>Kerman, Benjamin J.</creator><creator>Kraft, Peter</creator><creator>Kulkarni, Preetika</creator><creator>Lewis, Anna C.F.</creator><creator>Lubitz, Steven A.</creator><creator>Natarajan, Pradeep</creator><creator>Antwi, Ashley A.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6113-5564</orcidid></search><sort><creationdate>20231102</creationdate><title>The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care</title><author>Vassy, Jason L. ; Brunette, Charles A. ; Lebo, Matthew S. ; MacIsaac, Katharine ; Yi, Thomas ; Danowski, Morgan E. ; Alexander, Nicholas V.J. ; Cardellino, Mark P. ; Christensen, Kurt D. ; Gala, Manish ; Green, Robert C. ; Harris, Elizabeth ; Jones, Natalie E. ; Kerman, Benjamin J. ; Kraft, Peter ; Kulkarni, Preetika ; Lewis, Anna C.F. ; Lubitz, Steven A. ; Natarajan, Pradeep ; Antwi, Ashley A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-3ec63d209155b7dc3a1ad8a2eecf563c66f27e64512900d49e9622c5082eddc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>Male</topic><topic>Primary Health Care</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vassy, Jason L.</creatorcontrib><creatorcontrib>Brunette, Charles A.</creatorcontrib><creatorcontrib>Lebo, Matthew S.</creatorcontrib><creatorcontrib>MacIsaac, Katharine</creatorcontrib><creatorcontrib>Yi, Thomas</creatorcontrib><creatorcontrib>Danowski, Morgan E.</creatorcontrib><creatorcontrib>Alexander, Nicholas V.J.</creatorcontrib><creatorcontrib>Cardellino, Mark P.</creatorcontrib><creatorcontrib>Christensen, Kurt D.</creatorcontrib><creatorcontrib>Gala, Manish</creatorcontrib><creatorcontrib>Green, Robert C.</creatorcontrib><creatorcontrib>Harris, Elizabeth</creatorcontrib><creatorcontrib>Jones, Natalie E.</creatorcontrib><creatorcontrib>Kerman, Benjamin J.</creatorcontrib><creatorcontrib>Kraft, Peter</creatorcontrib><creatorcontrib>Kulkarni, Preetika</creatorcontrib><creatorcontrib>Lewis, Anna C.F.</creatorcontrib><creatorcontrib>Lubitz, Steven A.</creatorcontrib><creatorcontrib>Natarajan, Pradeep</creatorcontrib><creatorcontrib>Antwi, Ashley A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of human genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vassy, Jason L.</au><au>Brunette, Charles A.</au><au>Lebo, Matthew S.</au><au>MacIsaac, Katharine</au><au>Yi, Thomas</au><au>Danowski, Morgan E.</au><au>Alexander, Nicholas V.J.</au><au>Cardellino, Mark P.</au><au>Christensen, Kurt D.</au><au>Gala, Manish</au><au>Green, Robert C.</au><au>Harris, Elizabeth</au><au>Jones, Natalie E.</au><au>Kerman, Benjamin J.</au><au>Kraft, Peter</au><au>Kulkarni, Preetika</au><au>Lewis, Anna C.F.</au><au>Lubitz, Steven A.</au><au>Natarajan, Pradeep</au><au>Antwi, Ashley A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care</atitle><jtitle>American journal of human genetics</jtitle><addtitle>Am J Hum Genet</addtitle><date>2023-11-02</date><risdate>2023</risdate><volume>110</volume><issue>11</issue><spage>1841</spage><epage>1852</epage><pages>1841-1852</pages><issn>0002-9297</issn><eissn>1537-6605</eissn><abstract>Polygenic risk scores (PRSs) hold promise for disease risk assessment and prevention. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRSs in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities. The study processes used to test patients, report their PRS results to them and their primary care providers (PCPs), and promote the use of those results in clinical decision-making are modeled on common practices in primary care. The following diseases were chosen for their prevalence and familiarity to PCPs: coronary artery disease; type 2 diabetes; atrial fibrillation; and breast, colorectal, and prostate cancers. A randomized clinical trial (RCT) design and primary outcome of time-to-new-diagnosis of a target disease bring methodological rigor to the question of the clinical utility of PRS implementation. The study’s pragmatic RCT design enhances its relevance to how PRS might reasonably be implemented in primary care. Steps the study has taken to promote health equity include the thoughtful handling of genetic ancestry in PRS construction and reporting and enhanced recruitment strategies to address underrepresentation in research participation. To date, enhanced recruitment efforts have been both necessary and successful: participants of underrepresented race and ethnicity groups have been less likely to enroll in the study than expected but ultimately achieved proportional representation through targeted efforts. The GenoVA Study experience to date offers insights for evaluating the clinical utility of equitable PRS implementation in adult primary care. The Genomic Medicine at Veterans Affairs (GenoVA) Study is addressing three main challenges to the clinical implementation of PRS in preventive care: defining and determining their clinical utility, implementing them in time-constrained primary care settings, and countering their potential to exacerbate healthcare disparities.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37922883</pmid><doi>10.1016/j.ajhg.2023.10.001</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6113-5564</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9297
ispartof American journal of human genetics, 2023-11, Vol.110 (11), p.1841-1852
issn 0002-9297
1537-6605
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10645559
source MEDLINE; PMC (PubMed Central); Elsevier ScienceDirect Journals Complete; Cell Press Free Archives; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Diabetes Mellitus, Type 2 - genetics
Genetic Predisposition to Disease
Humans
Male
Primary Health Care
Prostatic Neoplasms - genetics
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
title The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T06%3A05%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20GenoVA%20study:%20Equitable%20implementation%20of%20a%20pragmatic%20randomized%20trial%20of%20polygenic-risk%20scoring%20in%20primary%20care&rft.jtitle=American%20journal%20of%20human%20genetics&rft.au=Vassy,%20Jason%20L.&rft.date=2023-11-02&rft.volume=110&rft.issue=11&rft.spage=1841&rft.epage=1852&rft.pages=1841-1852&rft.issn=0002-9297&rft.eissn=1537-6605&rft_id=info:doi/10.1016/j.ajhg.2023.10.001&rft_dat=%3Cproquest_pubme%3E2886602555%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2886602555&rft_id=info:pmid/37922883&rft_els_id=S0002929723003543&rfr_iscdi=true